Does One Voriconazole Breakpoint Suit All Candida Species?

Documenti analoghi

• Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for Candida albicans Using a Validated In Vitro Pharmacokinetic/Pharmacodynamic Model
  di: Beredaki, Maria-Ioanna, et al.
  Pubblicazione: (2020)
• Caspofungin Etest Susceptibility Testing of Candida Species: Risk of Misclassification of Susceptible Isolates of C. glabrata and C. krusei when Adopting the Revised CLSI Caspofungin Breakpoints
  di: Arendrup, Maiken Cavling, et al.
  Pubblicazione: (2012)
• Breakpoints for Susceptibility Testing Should Not Divide Wild-Type Distributions of Important Target Species
  di: Arendrup, Maiken Cavling, et al.
  Pubblicazione: (2009)
• Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints
  di: Pfaller, M. A., et al.
  Pubblicazione: (2006)
• Evaluation of CLSI M44-A2 Disk Diffusion and Associated Breakpoint Testing of Caspofungin and Micafungin Using a Well-Characterized Panel of Wild-Type and fks Hot Spot Mutant Candida Isolates
  di: Arendrup, Maiken Cavling, et al.
  Pubblicazione: (2011)